Production (Stage)
Interpace Biosciences, Inc.
IDXG
$0.80
$0.022.56%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 48.17M | 46.83M | 44.62M | 41.40M | 40.39M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 48.17M | 46.83M | 44.62M | 41.40M | 40.39M |
| Cost of Revenue | 16.94M | 16.67M | 16.08M | 15.42M | 15.00M |
| Gross Profit | 31.22M | 30.17M | 28.54M | 25.98M | 25.39M |
| SG&A Expenses | 21.45M | 21.14M | 20.13M | 19.35M | 19.82M |
| Depreciation & Amortization | -- | -- | 27.00K | 226.00K | 544.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 39.11M | 38.48M | 36.87M | 35.58M | 35.99M |
| Operating Income | 9.06M | 8.35M | 7.75M | 5.83M | 4.40M |
| Income Before Tax | 8.15M | 7.19M | 6.29M | 4.40M | 2.66M |
| Income Tax Expenses | 18.00K | 4.00K | 17.00K | 17.00K | 17.00K |
| Earnings from Continuing Operations | 8.13 | 7.19 | 6.28 | 4.39 | 2.65 |
| Earnings from Discontinued Operations | -247.00K | -244.00K | -185.00K | -189.00K | -335.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 7.88M | 6.94M | 6.09M | 4.20M | 2.31M |
| EBIT | 9.06M | 8.35M | 7.75M | 5.83M | 4.40M |
| EBITDA | 9.41M | 8.65M | 8.03M | 6.26M | 5.12M |
| EPS Basic | 1.69 | 1.48 | 1.40 | 0.96 | 0.53 |
| Normalized Basic EPS | 1.16 | 1.02 | 0.90 | 0.63 | 0.38 |
| EPS Diluted | 0.87 | 0.97 | 1.39 | 0.96 | 0.53 |
| Normalized Diluted EPS | 0.57 | 0.65 | 0.90 | 0.63 | 0.38 |
| Average Basic Shares Outstanding | 17.60M | 17.55M | 17.47M | 17.40M | 17.33M |
| Average Diluted Shares Outstanding | 86.25M | 62.93M | 17.55M | 17.44M | 17.36M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |